Kunde Shalvi Sinai, Ghosh Ritushree, Wairkar Sarika
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, Maharashtra 400056, India.
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, Maharashtra 400056, India.
Drug Discov Today. 2022 May;27(5):1474-1482. doi: 10.1016/j.drudis.2022.02.003. Epub 2022 Feb 7.
Over the years, a tendency toward biopharmaceutical products as therapeutics has been witnessed compared with small molecular drugs. Biopharmaceuticals possess greater specificity, selectivity and potency with fewer side effects. The pulmonary route is a potential noninvasive route studied for the delivery of various molecules, including biopharmaceuticals. It directly delivers drugs to the lungs in higher concentrations and provides greater bioavailability than other noninvasive routes. This review focuses on the pulmonary route for the delivery of biopharmaceuticals. We have covered various biopharmaceuticals, including peptides, recombinant proteins, enzymes, monoclonal antibodies and nucleic acids, administered via a pulmonary route and discussed their rewards and drawbacks.
多年来，与小分子药物相比，生物制药产品作为治疗药物的趋势日益明显。生物制药具有更高的特异性、选择性和效力，且副作用更少。肺部给药途径是一种潜在的非侵入性给药途径，可用于递送包括生物制药在内的各种分子。它能以更高的浓度将药物直接递送至肺部，比其他非侵入性给药途径具有更高的生物利用度。本综述聚焦于生物制药的肺部给药途径。我们涵盖了通过肺部给药途径施用的各种生物制药，包括肽、重组蛋白、酶、单克隆抗体和核酸，并讨论了它们的优缺点。
